<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes of secondary and tertiary adrenal insufficiency in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes of secondary and tertiary adrenal insufficiency in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes of secondary and tertiary adrenal insufficiency in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adrenal insufficiency can be caused by diseases of the adrenal gland (primary), interference with corticotropin (ACTH) secretion by the pituitary gland (secondary), or interference with corticotropin-releasing hormone (CRH) secretion by the hypothalamus (tertiary). Secondary and tertiary adrenal insufficiency are also called central adrenal insufficiency. The hallmark laboratory finding is an inappropriately low ACTH value in the setting of diminished cortisol concentrations. This topic will review the major causes of these disorders; the causes of primary adrenal insufficiency and the clinical manifestations and approach to diagnosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SECONDARY ADRENAL INSUFFICIENCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any process that involves the pituitary and interferes with corticotropin (ACTH) secretion can cause secondary adrenal insufficiency. The ACTH deficiency may be isolated or occur in conjunction with other pituitary hormone deficiencies (panhypopituitarism) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Panhypopituitarism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any disease that affects the pituitary gland can result in diminished secretion of one or more pituitary hormones. Pituitary tissue can be destroyed and hormone secretion reduced by large pituitary tumors or craniopharyngiomas, infectious diseases such as tuberculosis or histoplasmosis, infiltrative diseases, lymphocytic hypophysitis, head trauma, and large intracranial artery aneurysms (
         <a class="graphic graphic_table graphicRef55951" href="/z/d/graphic/55951.html" rel="external">
          table 1
         </a>
         ). Pituitary infarction can occur at the time of delivery if excessive blood is lost and hypotension occurs (Sheehan syndrome), and hemorrhage may occur into a pituitary tumor (pituitary apoplexy). Pituitary metastases are sometimes (approximately 5 percent) found in patients with disseminated cancer at autopsy; however, these metastases rarely reduce hormone secretion [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">
          "Causes of hypopituitarism"
         </a>
         .)
        </p>
        <p>
         Combined pituitary hormone deficiency (including ACTH deficiency) due to genetic pituitary abnormalities is rare. ACTH and cortisol deficiency have been described in patients with multiple pituitary hormone deficiencies due to mutations in the
         <em>
          PROP-1
         </em>
         (Prophet of Pit-1) gene, even though
         <em>
          PROP-1
         </em>
         is not expressed in corticotrophs. The onset of cortisol deficiency, which may be severe, ranges from childhood to late adulthood [
         <a href="#rid3">
          3-6
         </a>
         ]. Mutations in other transcription factors involved in early pituitary development (HESX1, LHX4) also can result in variable degrees of hypopituitarism that include ACTH deficiency [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">
          "Causes of hypopituitarism", section on 'Genetic diseases'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Isolated ACTH deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isolated corticotropin (ACTH) deficiency is a rare disorder [
         <a href="#rid9">
          9
         </a>
         ]. The defect is probably at the pituitary level because there is no ACTH secretory response to corticotropin-releasing hormone (CRH) or vasopressin, as there usually is in hypothalamic disorders [
         <a href="#rid10">
          10-12
         </a>
         ]. Occasional patients may have hypothyroxinemia and hyperprolactinemia that are corrected with glucocorticoid replacement [
         <a href="#rid13">
          13,14
         </a>
         ]. Anti-ACTH antibodies are present in some patients, some of whom had repeated administration of cosyntropin [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H346127370">
         <span class="h3">
          Autoimmune
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following observations suggest that most cases are caused by an autoimmune process:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequent association with other autoimmune endocrine disorders [
         <a href="#rid14">
          14
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of lymphocytic hypophysitis with selective corticotroph absence in some patients [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of antipituitary antibodies in the serum of 10 of 21 patients in one report [
         <a href="#rid17">
          17
         </a>
         ] and the presence of anti-corticotroph antibodies in the serum of at least one patient [
         <a href="#rid18">
          18
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         A novel syndrome, referred to as triple H syndrome, of isolated ACTH deficiency and alopecia areata has been described in two women and one man [
         <a href="#rid19">
          19,20
         </a>
         ]. One woman also had vitiligo and anterograde memory loss, and a magnetic resonance imaging (MRI) scan revealed hippocampal atrophy [
         <a href="#rid19">
          19
         </a>
         ]. A skin biopsy from the male patient showed lymphocytic invasion surrounding the hair follicles [
         <a href="#rid20">
          20
         </a>
         ]. The authors postulated an autoimmune target molecule shared among the hypothalamus (or pituitary corticotrophs), hair follicles, and hippocampus.
        </p>
        <p class="headingAnchor" id="H346127377">
         <span class="h3">
          Genetic causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three extremely rare genetic conditions can cause isolated ACTH deficiency.
        </p>
        <p class="headingAnchor" id="H346127458">
         <span class="h4">
          Mutations in the POMC gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rare syndrome of early-onset obesity and secondary adrenal insufficiency, usually with red hair, has been attributed to 12 homozygous or compound heterozygous loss-of-function mutations in the proopiomelanocortin (
         <em>
          POMC
         </em>
         ) gene [
         <a href="#rid21">
          21
         </a>
         ]. Their heterozygote relatives were unaffected, indicating a recessive mode of inheritance.
        </p>
        <p>
         This syndrome has been reproduced in homozygous,
         <em>
          POMC
         </em>
         gene knockout mice [
         <a href="#rid22">
          22
         </a>
         ]. Daily intraperitoneal injection of alpha-melanocyte-stimulating hormone (alpha-MSH) resulted in decreased food consumption, loss of weight, and darkening of coat color that reversed when the alpha-MSH was stopped. These results suggest that obesity in humans with
         <em>
          POMC
         </em>
         gene defects and possibly other causes of obesity may be treated with agonists specific for the brain melanocortin-4 receptor.
        </p>
        <p>
         Several
         <em>
          POMC
         </em>
         mutations and polymorphisms have also been detected in 96 extremely obese children and adolescents; 60 healthy, underweight subjects; and 46 patients with anorexia nervosa, none of which was regularly associated with a particular phenotype [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H346127466">
         <span class="h4">
          Cleavage enzyme defect
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another cause of isolated ACTH deficiency is a congenital defect leading to impaired function of prohormone convertase 1 (PC1), which cleaves ACTH from POMC [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H346127473">
         <span class="h4">
          TPIT gene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         TPIT is a transcription factor necessary for differentiation of the corticotroph cell and POMC production;
         <em>
          TPIT
         </em>
         gene mutations may be the most common genetic cause of neonatal isolated ACTH deficiency. In one report of 27 neonates with isolated ACTH deficiency, homozygous or compound, heterozygous mutations in the coding region of the
         <em>
          TPIT
         </em>
         gene were found in 17 of 27 neonates [
         <a href="#rid25">
          25
         </a>
         ]. All parents of the neonates with
         <em>
          TPIT
         </em>
         mutations were unaffected carriers, confirming a recessive mode of inheritance. Although isolated ACTH deficiency due to
         <em>
          TPIT
         </em>
         mutations is a rare disorder, prenatal diagnosis for families at risk would be beneficial as neonatal isolated ACTH deficiency from any cause, if not diagnosed and treated early, can result in death.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Familial corticosteroid-binding globulin (CBG, transcortin) deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         This rare syndrome may be misdiagnosed as isolated ACTH deficiency. It is caused by point mutations that reduce the affinity of CBG for cortisol (CBG Leuven and CBG Lyon) or null mutations that result in complete CBG deficiency [
         <a href="#rid26">
          26
         </a>
         ]. Some patients who are homozygous for these mutations have chronic fatigue and relative hypotension and may meet criteria for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); and others have chronic pain resembling fibromyalgia [
         <a href="#rid26">
          26
         </a>
         ]; while others have fatigue but normal blood pressure [
         <a href="#rid27">
          27
         </a>
         ]. Their morning serum cortisol concentrations are less than 1.8 mcg/dL (50 nmol/L). Serum free cortisol, 24-hour urinary free cortisol, and plasma ACTH concentrations are normal. The low serum cortisol and normal plasma ACTH concentrations may lead to misdiagnosis of isolated ACTH deficiency [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Traumatic brain injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although traumatic brain injury most often causes growth hormone and/or gonadotropin deficiency, ACTH deficiency occurred in 8 percent of 611 patients in one meta-analysis [
         <a href="#rid28">
          28
         </a>
         ]. Although traumatic brain injury is most often suspected after automobile accidents or falls, some studies demonstrate that injuries sustained during boxing and soccer may cause hypopituitarism [
         <a href="#rid29">
          29,30
         </a>
         ]. This topic is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">
          "Causes of hypopituitarism", section on 'Traumatic brain injury'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H290041754">
         <span class="h2">
          Drugs
         </span>
        </p>
        <p class="headingAnchor" id="H290041761">
         <span class="h3">
          High-dose progestins
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          Megestrol acetate
         </a>
         is used to treat patients with metastatic breast cancer and to increase appetite in patients with cancer anorexia/cachexia and wasting diseases such as acquired immunodeficiency syndrome (AIDS). This progestin has some glucocorticoid activity via binding to the glucocorticoid receptor. As a result, they may present with cushingoid features and their withdrawal can occasionally cause secondary adrenal insufficiency [
         <a href="#rid31">
          31-35
         </a>
         ]. This has been reported with daily doses of 160 mg or more. (See
         <a class="medical medical_review" href="/z/d/html/2816.html" rel="external">
          "Management of cancer anorexia/cachexia", section on 'Progesterone analogs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/778.html" rel="external">
          "Treatment for hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Later-line therapy'
         </a>
         .)
        </p>
        <p>
         Adrenal insufficiency may also occur
         <strong>
          during
         </strong>
         megestrol therapy, presenting with symptoms such as fatigue and weakness, and manifested by a poor response to ACTH stimulation [
         <a href="#rid36">
          36
         </a>
         ]. In one study, 43 percent of 28 hospitalized patients taking megestrol, 800 mg daily, had morning cortisol levels less than 5 mcg/dL (138 nmol/L) [
         <a href="#rid37">
          37
         </a>
         ]. Another study of 30 patients taking 160 to 320 mg daily found subnormal cortisol responses to a low-dose
         <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">
          ACTH stimulation test
         </a>
         (0.625 mcg/1.73 m
         <sup>
          2
         </sup>
         ) in 16 patients, 9 of whom had morning cortisol values less than 5 mcg/dL (138 nmol/L) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Regardless of the mechanism, clinicians should be alert to the possibility of hypothalamic-pituitary-adrenal suppression or drug-induced Cushing syndrome in patients who receive chronic
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         or other high-dose progestins and of secondary adrenal insufficiency in those who discontinue the drug.
        </p>
        <p class="headingAnchor" id="H290041768">
         <span class="h3">
          Opiates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic administration of opiates has the potential to cause secondary adrenal insufficiency, as shown by studies of patients receiving a variety of oral or transdermal agents [
         <a href="#rid39">
          39-41
         </a>
         ]. To compare the effects of these agents, daily doses were expressed as the morphine-equivalent daily dose (MEDD). Although not absolute, in general, patients with MEED of 100 mg or greater were most likely to have adrenal insufficiency, with rates ranging from 10 to 50 percent. Similar findings were reported with chronic intrathecal administration of
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         or
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         (MEED 2 to 10 mg) [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
         Acute administration of
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         decreases afternoon cortisol secretion [
         <a href="#rid44">
          44
         </a>
         ], and the use of
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         anesthesia blocks the usual increase in cortisol levels during surgery [
         <a href="#rid45">
          45
         </a>
         ], but these effects are short lived.
        </p>
        <p class="headingAnchor" id="H2870784631">
         <span class="h3">
          Immune checkpoint inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune checkpoint inhibitors can cause hypophysitis and panhypopituitarism, including ACTH deficiency, which is more common in those receiving cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies than in those receiving anti-programmed cell death 1 (PD-1), and anti-programmed cell death 1 ligand (PD-L1) antibodies [
         <a href="#rid18">
          18
         </a>
         ]. However, some reports suggest a milder presentation of hypophysitis, with either fatigue or no symptoms, in up to 10 percent of individuals receiving anti-PD-1 therapy [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Hypophysitis'
         </a>
         .)
        </p>
        <p>
         Although an uncommon adverse reaction, immune checkpoint inhibitors, especially the PD-1 and PD-L1 antibodies, also have been associated with isolated ACTH deficiency [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TERTIARY ADRENAL INSUFFICIENCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tertiary adrenal insufficiency refers to hypothalamic abnormalities that reduce corticotropin-releasing hormone (CRH) secretion. The most common causes of tertiary adrenal insufficiency, shown below, also suppress corticotropin (ACTH) secretion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abrupt cessation of high-dose glucocorticoid therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction (cure) of hypercortisolism (Cushing syndrome)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Chronic high-dose glucocorticoid therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Suppression of hypothalamic-pituitary-adrenal function by chronic administration of high doses of glucocorticoids is the most common cause of tertiary adrenal insufficiency. Glucocorticoids may induce adrenal insufficiency, even if given in a dose that normally would not suppress the axis, if their metabolism is reduced by a drug interaction, generally by concomitant administration of a potent CYP3A4 inhibitor. This can occur, for example, when
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         and glucocorticoids are both given [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal"
         </a>
         .)
        </p>
        <p>
         High doses of glucocorticoids decrease hypothalamic CRH synthesis and secretion. They also block the trophic and ACTH secretagogue actions of CRH on the anterior pituitary. This results in decreased synthesis of proopiomelanocortin (POMC) and decreased secretion of ACTH and other POMC-derived peptides by the pituitary corticotrophs. As a result, pituitary corticotrophs decrease in size, and eventually, the number of identifiable corticotrophs decreases [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         In the absence of ACTH stimulation, the zona fasciculata and zona reticularis of the adrenal atrophy and can no longer produce cortisol. Clinical features of secondary and tertiary adrenal insufficiency that help distinguish them from primary adrenal insufficiency include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cortisol production can be restored by prolonged ACTH administration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mineralocorticoid secretion is nearly normal because this function depends mostly on the renin-angiotensin system rather than on ACTH (see
         <a class="medical medical_review" href="/z/d/html/157.html" rel="external">
          "Diagnosis of adrenal insufficiency in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         A thorough history regarding medications, creams, and supplements should be obtained in every patient with apparent secondary or tertiary adrenal insufficiency. Glucocorticoids may be taken via the oral, ocular, inhaled, transdermal, rectal, or parenteral routes, all of which should be considered. Additionally, these compounds may be present in bleaching creams and herbal preparations and may not be reported as a "medication" unless specifically queried [
         <a href="#rid51">
          51
         </a>
         ]. Finally, patients should be asked about any recent therapeutic injections (ie, joint, spine) as many patients are unaware that these contain glucocorticoids. Measurement of exogenous steroids in urine may help to establish the cause and estimate time to recovery if the suppression of hypothalamic-pituitary function has occurred as a result of a synthetic glucocorticoid injection [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          After the cure of Cushing syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tertiary adrenal insufficiency occurs in otherwise untreated patients who are cured of Cushing syndrome by removal of a pituitary or nonpituitary ACTH-secreting or a cortisol-secreting adrenal tumor. The chronically high serum cortisol concentrations before surgery suppress the hypothalamic-pituitary-adrenal axis in the same manner as chronic administration of high doses of glucocorticoids.
        </p>
        <p>
         For example, patients who achieve remission after transsphenoidal surgery for ACTH-secreting pituitary tumors are typically hypocortisolemic for up to 12 months postoperatively and require glucocorticoid replacement therapy, which must be supplemented during stress. This issue is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118.html" rel="external">
          "Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Perioperative glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Other causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any process that involves the hypothalamus and interferes with CRH secretion will result in tertiary adrenal insufficiency. Such processes include: tumors, infiltrative diseases such as sarcoidosis, and cranial radiation [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">
          "Causes of hypopituitarism", section on 'Hypothalamic disorders'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">
          "Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood", section on 'Adrenocorticotropic hormone deficiency'
         </a>
         .)
        </p>
        <p>
         A rare cause is isolated CRH deficiency in the absence of other apparent disease; the diagnosis is suggested by a poor response of ACTH during an insulin tolerance test but a good response to CRH [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         One of the features of Prader-Willi syndrome is hypothalamic dysfunction, resulting in growth hormone and gonadotropin hormone deficiencies. In addition, some of these patients may also have partial adrenal insufficiency. Because of the high annual death rate in Prader-Willi syndrome, and the theoretical possibility of ACTH deficiency, adrenal function was investigated using the
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         stimulation test in 25 children with genetically confirmed Prader-Willi syndrome. Of these, 15 failed to show a normal ACTH response, and 7 of 11 in whom 11-deoxycortisol levels were measured had an abnormal response, suggesting partial adrenal insufficiency [
         <a href="#rid55">
          55
         </a>
         ]. However, at least some of the latter group failed to show adequate cortisol suppression, bringing the diagnosis of adrenal insufficiency into question. Three other studies of a total of 160 patients found normal adrenal function in 159 patients using the 250 mcg ACTH test, the metyrapone stimulation test, and/or an insulin tolerance test [
         <a href="#rid56">
          56-58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5864.html" rel="external">
          "Prader-Willi syndrome: Management", section on 'Hypothalamic and pituitary dysfunction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H290042235">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types of adrenal insufficiency
         </strong>
         – Adrenal insufficiency can be caused by diseases of the adrenal gland (primary), interference with corticotropin (ACTH) secretion by the pituitary gland (secondary), or interference with corticotropin-releasing hormone (CRH) secretion by the hypothalamus (tertiary). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary adrenal insufficiency
         </strong>
         – Any process that involves the pituitary and interferes with ACTH secretion can cause secondary adrenal insufficiency. The ACTH deficiency may be isolated or occur in conjunction with other pituitary hormone deficiencies (panhypopituitarism) (
         <a class="graphic graphic_table graphicRef55951" href="/z/d/graphic/55951.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Secondary adrenal insufficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Isolated ACTH deficiency
         </strong>
         – Isolated ACTH deficiency is a rare disorder. Some cases are thought to be due to an autoimmune process (see
         <a class="local">
          'Autoimmune'
         </a>
         above). Genetic causes include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Loss-of-function mutations in the proopiomelanocortin (
         <em>
          POMC
         </em>
         ) gene resulting in a syndrome of early-onset obesity and secondary adrenal insufficiency (see
         <a class="local">
          'Mutations in the POMC gene'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ACTH deficiency due to a defect in the enzyme that cleaves ACTH from POMC (see
         <a class="local">
          'Cleavage enzyme defect'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          TPIT
         </em>
         gene mutations resulting in neonatal isolated ACTH deficiency (see
         <a class="local">
          'TPIT gene mutations'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other causes of secondary adrenal insufficiency
         </strong>
         – Other causes of secondary adrenal insufficiency include traumatic brain injury and drugs (chronic use of high-dose progestins, opiates, or immune checkpoint inhibitors). (See
         <a class="local">
          'Traumatic brain injury'
         </a>
         above and
         <a class="local">
          'Drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Familial corticosteroid-binding globulin deficiency
         </strong>
         – Patients with familial corticosteroid-binding globulin (CBG) deficiency have low total serum cortisol levels and may present with fatigue, leading to a false diagnosis of adrenal sufficiency due to isolated ACTH deficiency. However, free cortisol levels in serum, urine, and saliva are normal, as is plasma ACTH. (See
         <a class="local">
          'Familial corticosteroid-binding globulin (CBG, transcortin) deficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tertiary adrenal insufficiency
         </strong>
         – Tertiary adrenal insufficiency refers to deficient CRH secretion that results from hypothalamic dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic high-dose glucocorticoid therapy
         </strong>
         – Suppression of hypothalamic-pituitary-adrenal function by chronic administration of high doses of glucocorticoids is the most common cause of tertiary adrenal insufficiency. Clinical features of secondary and tertiary adrenal insufficiency that help distinguish them from primary adrenal insufficiency include: cortisol production can be restored by prolonged ACTH administration, and mineralocorticoid secretion is nearly normal because this function depends mostly on the renin-angiotensin system rather than on ACTH. (See
         <a class="local">
          'Chronic high-dose glucocorticoid therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          After cure of Cushing syndrome
         </strong>
         – Tertiary adrenal insufficiency also occurs in patients who are cured of Cushing syndrome by removal of a pituitary or nonpituitary ACTH-secreting tumor or a cortisol-secreting adrenal tumor. The chronically high serum cortisol concentrations before treatment suppress the hypothalamic-pituitary-adrenal axis in the same manner as chronic administration of high doses of glucocorticoids. (See
         <a class="local">
          'After the cure of Cushing syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1555582414">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Grossman AB. Clinical Review#: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010; 95:4855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modhi G, Bauman W, Nicolis G. Adrenal failure associated with hypothalamic and adrenal metastases: A case report and review of the literature. Cancer 1981; 47:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pernasetti F, Toledo SP, Vasilyev VV, et al. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000; 85:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal G, Bhatia V, Cook S, Thomas PQ. Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. J Clin Endocrinol Metab 2000; 85:4556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parks JS, Brown MR, Hurley DL, et al. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84:4362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böttner A, Keller E, Kratzsch J, et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab 2004; 89:5256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machinis K, Pantel J, Netchine I, et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coutinho E, Brandão CM, Lemos MC. Combined Pituitary Hormone Deficiency Caused by a Synonymous HESX1 Gene Mutation. J Clin Endocrinol Metab 2019; 104:2851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacpoole PW, Interlandi JW, Nicholson WE, Rabin D. Isolated ACTH deficiency: a heterogeneous disorder. Critical review and report of four new cases. Medicine (Baltimore) 1982; 61:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida T, Arai T, Sugano J, et al. Isolated ACTH deficiency accompanied by 'primary hypothyroidism' and hyperprolactinaemia. Acta Endocrinol (Copenh) 1983; 104:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koide Y, Kimura S, Inoue S, et al. Responsiveness of hypophyseal-adrenocortical axis to repetitive administration of synthetic ovine corticotropin-releasing hormone in patients with isolated adrenocorticotropin deficiency. J Clin Endocrinol Metab 1986; 63:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantalamessa L, Catania A, Baldini M, et al. CRH and lysine-vasopressin stimulation tests in the diagnosis of hypoadrenalism secondary to hypothalamic or pituitary disorders. Horm Metab Res 1990; 22:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanemaru Y, Noguchi T, Onaya T. Isolated ACTH deficiency associated with transient thyrotoxicosis and hyperprolactinemia. Endocrinol Jpn 1989; 36:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigemasa C, Kouchi T, Ueta Y, et al. Evaluation of thyroid function in patients with isolated adrenocorticotropin deficiency. Am J Med Sci 1992; 304:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan EH, MacArthur K, Mitchell AL, et al. Spontaneous and tetracosactide-induced anti-ACTH antibodies in man. Clin Endocrinol (Oxf) 2016; 84:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen MD, Handwerger BS, Scheithauer BW, et al. Lymphocytic hypophysitis with isolated corticotropin deficiency. Ann Intern Med 1986; 105:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiura M, Hashimoto A, Shizawa M, et al. Heterogeneity of anterior pituitary cell antibodies detected in insulin-dependent diabetes mellitus and adrenocorticotropic hormone deficiency. Diabetes Res 1986; 3:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauter NP, Toni R, McLaughlin CD, et al. Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides. J Clin Endocrinol Metab 1990; 70:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farooqi IS, Jones MK, Evans M, et al. Triple H syndrome: a novel autoimmune endocrinopathy characterized by dysfunction of the hippocampus, hair follicle, and hypothalamic-pituitary adrenal axis. J Clin Endocrinol Metab 2000; 85:2644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichiki K, Nakamura T, Fujita N, et al. An endocrinopathy characterized by dysfunction of the pituitary-adrenal axis and alopecia universalis: supporting the entity of a triple H syndrome. Eur J Endocrinol 2002; 147:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark AJ. 60 YEARS OF POMC: The proopiomelanocortin gene: discovery, deletion and disease. J Mol Endocrinol 2016; 56:T27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinney A, Becker I, Heibült O, et al. Systematic mutation screening of the pro-opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes. J Clin Endocrinol Metab 1998; 83:3737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nussey SS, Soo SC, Gibson S, et al. Isolated congenital ACTH deficiency: a cleavage enzyme defect? Clin Endocrinol (Oxf) 1993; 39:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallette-Kasic S, Brue T, Pulichino AM, et al. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 2005; 90:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torpy DJ, Bachmann AW, Grice JE, et al. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001; 86:3692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perogamvros I, Underhill C, Henley DE, et al. Novel corticosteroid-binding globulin variant that lacks steroid binding activity. J Clin Endocrinol Metab 2010; 95:E142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bavisetty S, Bavisetty S, McArthur DL, et al. Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. Neurosurgery 2008; 62:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanriverdi F, Unluhizarci K, Kocyigit I, et al. Brief communication: pituitary volume and function in competing and retired male boxers. Ann Intern Med 2008; 148:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ives JC, Alderman M, Stred SE. Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male. J Athl Train 2007; 42:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik KJ, Wakelin K, Dean S, et al. Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate. Ann Clin Biochem 1996; 33 ( Pt 3):187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dux S, Bishara J, Marom D, et al. Medroxyprogesterone acetate-induced secondary adrenal insufficiency. Ann Pharmacother 1998; 32:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delitala AP, Fanciulli G, Maioli M, et al. Primary symptomatic adrenal insufficiency induced by megestrol acetate. Neth J Med 2013; 71:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian S, Goker H, Kanji A, Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 1997; 157:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ron IG, Soyfer V, Goldray D, et al. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002; 38:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chidakel AR, Zweig SB, Schlosser JR, et al. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006; 29:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valverde-Filho J, da Cunha Neto MB, Fonoff ET, et al. Chronic spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain patients. Pain Med 2015; 16:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li T, Cunningham JL, Gilliam WP, et al. Prevalence of Opioid-Induced Adrenal Insufficiency in Patients Taking Chronic Opioids. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibb FW, Stewart A, Walker BR, Strachan MW. Adrenal insufficiency in patients on long-term opioid analgesia. Clin Endocrinol (Oxf) 2016; 85:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norman JG, Fink GW. The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial. Am Surg 1997; 63:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garland EJ, Zis AP. Effect of codeine and oxazepam on afternoon cortisol secretion in men. Psychoneuroendocrinology 1989; 14:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JM, Reier CE, Lanese RR, Rower M. Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab 1974; 38:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducloux R, Tavernier JY, Wojewoda P, et al. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology. Ann Endocrinol (Paris) 2021; 82:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi I, Taura D, Hakata T, et al. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. Clin Endocrinol (Oxf) 2021; 94:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percik R, Shlomai G, Tirosh A, et al. Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev 2020; 19:102454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliot ER, Theodoraki A, Jain LR, et al. Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond) 2016; 16:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phifer RF, Spicer SS, Orth DN. Specific demonstration of the human hypophyseal cells which produce adrenocorticotropic hormone. J Clin Endocrinol Metab 1970; 31:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lansang MC, Farmer T, Kennedy L. Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections. Endocr Pract 2009; 15:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, et al. Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. J Clin Endocrinol Metab 2003; 88:3149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishihara E, Kimura H, Ishimaru T, et al. A case of adrenal insufficiency due to acquired hypothalamic CRH deficiency. Endocr J 1997; 44:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farholt S, Sode-Carlsen R, Christiansen JS, et al. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011; 96:E173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg AGW, Pellikaan K, Poitou C, et al. Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obrynba KS, Hoffman RP, Repaske DR, et al. No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test. J Pediatr Endocrinol Metab 2018; 31:809.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 173 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20719838" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical Review#: The diagnosis and management of central hypoadrenalism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Adrenal failure associated with hypothalamic and adrenal metastases: A case report and review of the literature
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634415" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11134108" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10599689" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Heritable disorders of pituitary development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472232" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11567216" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30888394" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Combined Pituitary Hormone Deficiency Caused by a Synonymous HESX1 Gene Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6276646" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Isolated ACTH deficiency: a heterogeneous disorder. Critical review and report of four new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6318488" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Isolated ACTH deficiency accompanied by 'primary hypothyroidism' and hyperprolactinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3013917" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Responsiveness of hypophyseal-adrenocortical axis to repetitive administration of synthetic ovine corticotropin-releasing hormone in patients with isolated adrenocorticotropin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2169450" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : CRH and lysine-vasopressin stimulation tests in the diagnosis of hypoadrenalism secondary to hypothalamic or pituitary disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2555145" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Isolated ACTH deficiency associated with transient thyrotoxicosis and hyperprolactinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1332472" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Evaluation of thyroid function in patients with isolated adrenocorticotropin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25880719" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Spontaneous and tetracosactide-induced anti-ACTH antibodies in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3014939" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lymphocytic hypophysitis with isolated corticotropin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3011344" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Heterogeneity of anterior pituitary cell antibodies detected in insulin-dependent diabetes mellitus and adrenocorticotropic hormone deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2159484" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10946860" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Triple H syndrome: a novel autoimmune endocrinopathy characterized by dysfunction of the hippocampus, hair follicle, and hypothalamic-pituitary adrenal axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12213673" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : An endocrinopathy characterized by dysfunction of the pituitary-adrenal axis and alopecia universalis: supporting the entity of a triple H syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643913" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : 60 YEARS OF POMC: The proopiomelanocortin gene: discovery, deletion and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10470087" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768693" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Systematic mutation screening of the pro-opiomelanocortin gene: identification of several genetic variants including three different insertions, one nonsense and two missense point mutations in probands of different weight extremes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8222301" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Isolated congenital ACTH deficiency: a cleavage enzyme defect?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613420" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502797" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20610591" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Novel corticosteroid-binding globulin variant that lacks steroid binding activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580806" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519929" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Brief communication: pituitary volume and function in competing and retired male boxers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18060001" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9250225" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741369" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Induction of adrenal suppression by megestrol acetate in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8791979" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9475840" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Medroxyprogesterone acetate-induced secondary adrenal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23412818" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Primary symptomatic adrenal insufficiency induced by megestrol acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140272" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical adrenal insufficiency in patients receiving megestrol therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12110495" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16610239" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25521923" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Chronic spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32866966" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prevalence of Opioid-Induced Adrenal Insufficiency in Patients Taking Chronic Opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27260138" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Adrenal insufficiency in patients on long-term opioid analgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10852454" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Endocrine consequences of long-term intrathecal administration of opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8985076" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2813660" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of codeine and oxazepam on afternoon cortisol secretion in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4823919" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33290748" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33037658" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31838158" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27697800" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4195193" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Specific demonstration of the human hypophyseal cells which produce adrenocorticotropic hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377596" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Complications of chronic use of skin lightening cosmetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364690" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Diagnosing the unrecognized systemic absorption of intra-articular and epidural steroid injections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12843158" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9152624" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A case of adrenal insufficiency due to acquired hypothalamic CRH deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18303077" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20980432" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32232324" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29959886" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
